Fintepla has no substantial impact on growth, in terms of height and weight, in children with Dravet syndrome, clinical trial data suggest. The findings were shared at the 2020 American Epilepsy Society (AES) Annual Meeting, in the presentation, “Treatment with Fintepla (fenluramine) in Patients with Dravet Syndrome Has No Long-term Effect on Weight and Growth.” Fintepla (formerly ZX008) is an oral anti-seizure treatment for Dravet syndrome developed by Zogenix. The medication has been approved to treat Dravet…

You must be logged in to read/download the full post.